Clinical impact of novel anticoagulation strategies in sepsis

Current Opinion in Critical Care

Volumn 7, Issue 5, 2001, Pages 347-353

  Opal, Steven M ^a,b  

^a BROWN UNIVERSITY   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; DROTRECOGIN; HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; CRITICAL ILLNESS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; REVIEW; SEPSIS; SEPTIC SHOCK;

ANTICOAGULANTS; CLINICAL TRIALS, PHASE III; FIBRINOLYTIC AGENTS; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS;

EID: 0035162545     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200110000-00006     Document Type: Review

References (41)

1. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
2. Clinical trials for severe sepsis: Past failures and future hopes
3. New therapeutic implications of anticoagulation mediator replacement in sepsis and acute respiratory distress syndrome
4. Pathophysiology of disseminated intravascular coagulation in sepsis
5. Coagulation abnormalities in acute lung injury and sepsis
6. Review: Infectious diseases and coagulation disorders
7. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
8. Disseminated intravascular coagulation
9. Keep in contact: The role of the contact system in infection and sepsis
10. Role of the coagulation system in the local and systemic inflammatory response
11. Tissue factor pathway of coagulation in sepsis
12. Contact activation in shock caused by invasive group A Streptococcus pyogenes
13. Outer membrane vesicles from Neisseria meningitidis: Effects on tissue factor and plasminogen activator inhibitor-2 production in human monocytes
14. Coagulation system and platelets are fully activated in uncomplicated sepsis
15. Activation and inhibition of fibrinolysis in septic patients in an internal medicine intensive care unit
16. Modulation of hemostatic mechanisms in bacterial infectious diseases
17. Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?
18. 4G-5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease
19. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: Evidence that plasma TAFI antigen levels are strongly genetically controlled
20. High-dose antithrombin therapy for sepsis
21. Clinical trial results with antithrombin III in sepsis
22. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications
23. Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor
24. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis
25. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis
26. The protein data bank
27. The second kunitz domain of human tissue factor pathway inhibitor: Cloning, structure determination and interaction with factor Xa
28. Efficacy and safety of recombinant human activated protein C for severe sepsis
29. The phylogenetic relationships between the coagulation system and the inflammatory networks
30. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation
31. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin
32. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor-1
33. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex
34. The endothelial cell protein C receptor
35. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis
36. Endothelial cell protein C receptor plays an important role in protein C activation in vivo
37. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κB (NF-κB) and tumor necrosis factor α (TNF-α) production in the THP-1 monocytic cell line
38. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site
39. Endothelium function in sepsis
40. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood
41. Antithrombin III: Where are we? 3rd Jena International Symposium on Sepsis and Multiorgan Dysfunction